Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in ...

5 November 2026 · By · Wire by Fusion42

Published

5 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at hmpgloballearningnetwork.com →

◆ Verified

Fusion42 · 5 November 2026 · Fusion42 review

Following FDA approval, lirafugratinib has been recommended as a Category 2A preferred subsequent-line treatment by the NCCN for cholangiocarcinoma patients with FGFR2 fusions or rearrangements, based on strong clinical trial results showing significant response rates and manageable safety profiles.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now use lirafugratinib as a validated treatment for cholangiocarcinoma with FGFR2 alterations, so start patient molecular testing to access this new pathway and avoid being left behind in targeted therapy.

◆ Coverage

1 source · 5 Nov 2026

◆ Related on Wire

◆ Topics

Biotechlirafugratinibcholangiocarcinomafgfr2nccn-guidelinesfda-approval